Point-of-Care Diagnostics Global Market-Forecast to 2023

Publishing Date : May, 2017
Report Code : HCMD0146
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Point of care tests, also called near-patient testing or bedside testing, refers to the performance of diagnostic tests at or near the site where the patient is located and helps in obtaining accurate results in a very short period of time. It can be performed by non-laboratory personnel and the main benefit of POCT is to make tests more convenient and immediately to the patient that helps doctors/physician to receive the results quicker, enabling clinicians to support the timely diagnosis, monitoring, and treatment of patients. It can be performed by non-laboratory personnel and the results are used for clinical decision making. POCD is usually used in clinics, healthcare departments, hospitals, and patient’s homes. In hospitals, they are primarily performed in emergency departments, surgical suites, critical care units, and certain outpatient areas. POC tests can be performed by a wide variety of people can, including laboratory professionals, emergency first responders, radiologists, doctors, nurses, physician assistants, or other healthcare practitioners. They may even be done by patients, sometimes called "self-tests" or "home tests”. POCT has a range of complexity and procedures that vary from manual methodologies to automated analyzers. With the advancements in technology, POC testing analyzers are becoming smaller, faster, and more user-friendly and to achieve accuracy with increasingly smaller samples (body fluids). The point of care diagnostics global market is expected to grow at single digit CAGR to reach $26,331.1 million by 2023.


The Point of care diagnostics market is segmented based on their products, technology, prescription mode, sample types, end-users, and geography. The global POCD market by products is segmented into glucose monitoring kits, infectious diseases testing kits, coagulation monitoring kits, hematology testing kits, pregnancy and fertility testing kits, cardiometabolic testing kits, tumor/cancer markers, urinalysis kits, cholesterol testing kits, drugs-of-abuse testing kits and others. The glucose monitoring kits are further segmented into self-glucose monitoring and continuous glucose monitoring kits. The Infectious diseases kits are further divided into HIV testing kits, Hepatitis testing kits, Tropical diseases testing kits, tuberculosis testing kits, Healthcare–Associated infection testing kits, respiratory infections testing kits, and others. The coagulation monitoring testing kits are further segmented into Prothrombin Time(PT/INR) Testing Kits and Activated Clotting Time(ACT/APTT) Testing Kits. The Pregnancy and Fertility Testing Kits are further segmented into Pregnancy Testing Kits and Fertility Testing Kits. The Cardiometabolic Monitoring Kits further segmented into Cardiac Markers, Blood Gas/Electrolytes Testing Kits, HBA1C Testing Kits, and LIPID Testing Kits. By technology, the POCD market is divided into a biosensor,microfluidics/lab-on-a-chip technology, PCR technology, Immunochromatographic/lateral flow technology and others. Based on prescription mode, POCD market is segmented into prescription based tests and over the counter tests. By sample types, POCD market is divided into blood, urine, saliva and others. Based on end-users, POCD market is segmented into hospitals, home healthcare, clinics. Further, the POCD global market is separated by geographical regions into North America, Europe, Asia-pacific and Rest of the World.

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET OVERVIEW
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
    • 3.4     MARKET DYNAMICS
      • 3.4.1     DRIVERS AND OPPORTUNITIES
        • 3.4.1.1     RAPID RISE IN THE AGING POPULATION
        • 3.4.1.2     HIGH PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES
        • 3.4.1.3     LACK OF SKILLED LABORATORY TECHNICIANS IN EMERGING COUNTRIES
        • 3.4.1.4     RISING NUMBER OF CLIA-WAIVED POC TESTS
        • 3.4.1.5     RISING AWARENESS ABOUT POINT OF CARE DIAGNOSTICS IN DEVELOPING COUNTRIES
        • 3.4.1.6     TECHNOLOGICAL ADVANCEMENTS
      • 3.4.2     RESTRAINTS AND THREATS
        • 3.4.2.1     INCONSISTENT REIMBURSEMENT AND HIGH COST OF DEVICES
        • 3.4.2.2     STRINGENT REGULATORY REQUIREMENTS
        • 3.4.2.3     RISING INCIDENCE OF PRODUCT RECALLS
        • 3.4.2.4     ACCURACY ISSUES
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.
      • 3.5.2     EUROPE
      • 3.5.3     INDIA
      • 3.5.4     CHINA
      • 3.5.5     JAPAN
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.7     MARKET SHARE ANALYSIS
    • 3.8     TECHNOLOGICAL ADVANCEMENTS
      • 3.8.1     SMARTPHONE-BASED TECHNOLOGIES
      • 3.8.2     NANOBIOSENSOR
      • 3.8.3     SMART CONTACT LENSES
      • 3.8.4     LIQUID BIOPSY
    • 3.9     FUNDING SCENARIO
    • 3.10     SUPPLY CHAIN ANALYSIS
  • 4     POINT OF CARE DIAGNOSTICS GLOBAL MARKET, BY PRODUCTS
    • 4.1     INTRODUCTION
    • 4.2     GLUCOSE MONITORING KITS
      • 4.2.1     SELF-GLUCOSE MONITORING KITS
      • 4.2.2     CONTINUOUS GLUCOSE MONITORING KITS
    • 4.3     INFECTIOUS DISEASES TESTING KITS
      • 4.3.1     HIV TESTING KITS
      • 4.3.2     HEPATITIS TESTING KITS
      • 4.3.3     TROPICAL DISEASES TESTING KITS
      • 4.3.4     TUBERCULOSIS TESTING KITS
      • 4.3.5     HEALTHCARE-ASSOCIATED INFECTION TEST KITS
      • 4.3.6     RESPIRATORY INFECTIONS TESTING KITS
      • 4.3.7     OTHER INFECTIOUS DISEASE TESTING KITS.
      • 4.3.8     EBOLA VIRUS DISEASE
      • 4.3.9     SYPHILIS
    • 4.4     COAGULATION MONITORING KITS
      • 4.4.1     PROTHROMBIN TIME(PT/INR) TESTING KITS
      • 4.4.2     ACTIVATED CLOTTING TIME(ACT/APTT) TESTING KITS
    • 4.5     HEMATOLOGY TESTING KITS
    • 4.6     PREGNANCY AND FERTILITY TESTING KITS
      • 4.6.1.1     PREGNANCY TESTING KIT
      • 4.6.1.2     FERTILITY TESTING KIT
  • 4.7     CARDIOMETABOLIC MONITORING KITS
    • 4.7.1     CARDIAC MARKERS
    • 4.7.2     BLOOD GAS ANALYZERS/ELECTROLYTES TESTING KITS
    • 4.7.3     HBA1C TESTING KITS
    • 4.7.4     LIPID TESTING KITS
  • 4.8     TUMOR/CANCER MARKERS
  • 4.9     URINALYSIS
  • 4.10     CHOLESTEROL TESTING KITS
  • 4.11     DRUGS-OF-ABUSE TESTING KITS
  • 4.12     OTHERS
    • 4.12.1     OPHTHALMIC TESTING KITS
  • 4.13     GENETIC MARKERS/TESTING KITS
    • 4.13.1     THERAPEUTIC DRUG MONITORING TESTS
    • 4.13.2     BLOOD LACTATE TEST
  • 4.14     FAECAL OCCULT BLOOD TESTING KITS
  • 5     POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
    • 5.1     INTRODUCTION
    • 5.2     BIOSENSOR TECHNOLOGY
    • 5.3     IMMUNOCHROMATOGRAPHIC/LATERAL FLOW TECHNOLOGY
    • 5.4     POLYMERASE CHAIN REACTION(PCR) TECHNOLOGY
    • 5.5     MICROFLUIDIC/LAB-ON-A–CHIP TECHNOLOGY
    • 5.6     OTHER TECHNOLOGIES
  • 6     POINT OF CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE
    • 6.1     INTRODUCTION
      • 6.1.1     PRESCRIPTION BASED TESTING KITS
      • 6.1.2     OVER THE COUNTER(OTC) TESTING KITS MARKET
  • 7     POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE TYPE
    • 7.1     INTRODUCTION
      • 7.1.1     BLOOD
      • 7.1.2     URINE
      • 7.1.3     SALIVA
      • 7.1.4     OTHER
  • 8     POINT OF CARE DIAGNOSTICS GLOBAL MARKET, BY END USER
    • 8.1     INTRODUCTION
    • 8.2     CLINICS
    • 8.3     HOSPITALS
    • 8.4     HOME HEALTHCARE
    • 8.5     OTHER END-USERS
  • 9     REGIONAL MARKET ANALYSIS
    • 9.1     INTRODUCTION
    • 9.2     NORTH AMERICA
      • 9.2.1     U.S.
      • 9.2.2     OTHERS
    • 9.3     EUROPE
    • 9.4     GERMANY
      • 9.4.1     ITALY
      • 9.4.2     FRANCE
      • 9.4.3     OTHERS
    • 9.5     ASIA PACIFIC
      • 9.5.1     JAPAN
      • 9.5.2     CHINA
      • 9.5.3     INDIA
      • 9.5.4     OTHERS
    • 9.6     REST OF THE WORLD
      • 9.6.1     BRAZIL
      • 9.6.2     REST OF LATIN AMERICA
      • 9.6.3     MIDDLE EAST AND OTHERS
  • 10     COMPANY DEVELOPMENTS
    • 10.1     INTRODUCTION
    • 10.2     APPROVALS
    • 10.3     AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 10.4     NEW PRODUCT LAUNCH
    • 10.5     ACQUISITIONS
    • 10.6     OTHER DEVELOPMENTS
  • 11     MAJOR COMPANIES
    • 11.1     ABBOTT LABORATORIES, INC
      • 11.1.1     OVERVIEW
      • 11.1.2     FINANCIALS
      • 11.1.3     PRODUCT PORTFOLIO
      • 11.1.4     KEY DEVELOPMENTS
      • 11.1.5     BUSINESS STRATEGY
      • 11.1.6     SWOT ANALYSIS
    • 11.2     ASCENSIA DIABETES CARE HOLDINGS AG.
      • 11.2.1     OVERVIEW
      • 11.2.2     FINANCIALS
      • 11.2.3     PRODUCT PORTFOLIO
      • 11.2.4     KEY DEVELOPMENTS
      • 11.2.5     BUSINESS STRATEGY
      • 11.2.6     SWOT ANALYSIS
    • 11.3     BECTON DICKINSON AND COMPANY
      • 11.3.1     OVERVIEW
      • 11.3.2     FINANCIALS
      • 11.3.3     PRODUCT PORTFOLIO
      • 11.3.4     KEY DEVELOPMENTS
      • 11.3.5     BUSINESS STRATEGY
      • 11.3.6     SWOT ANALYSIS
    • 11.4     BIOMERIEUX
      • 11.4.1     OVERVIEW
      • 11.4.2     FINANCIALS
      • 11.4.3     PRODUCT PORTFOLIO
      • 11.4.4     KEY DEVELOPMENTS
      • 11.4.5     BUSINESS STRATEGY
      • 11.4.6     SWOT ANALYSIS
    • 11.5     DANAHER CORPORATION
      • 11.5.1     OVERVIEW
      • 11.5.2     FINANCIALS
      • 11.5.3     PRODUCT PORTFOLIO
      • 11.5.4     KEY DEVELOPMENTS
      • 11.5.5     BUSINESS STRATEGY
      • 11.5.6     SWOT ANALYSIS
    • 11.6     DEXCOM INC.
      • 11.6.1     OVERVIEW
      • 11.6.2     FINANCIALS
      • 11.6.3     PRODUCT PORTFOLIO
      • 11.6.4     KEY DEVELOPMENTS
      • 11.6.5     BUSINESS STRATEGY
      • 11.6.6     SWOT ANALYSIS
    • 11.7     F.HOFFMANN-LA ROCHE HOLDINGS AG
      • 11.7.1     OVERVIEW
      • 11.7.2     FINANCIALS
      • 11.7.3     PRODUCT PORTFOLIO
      • 11.7.4     KEY DEVELOPMENTS
      • 11.7.5     BUSINESS STRATEGY
      • 11.7.6     SWOT ANALYSIS
    • 11.8     JOHNSON & JOHNSON
      • 11.8.1     OVERVIEW
      • 11.8.2     FINANCIALS
      • 11.8.3     PRODUCT PORTFOLIO
      • 11.8.4     KEY DEVELOPMENTS
      • 11.8.5     BUSINESS STRATEGY
      • 11.8.6     SWOT ANALYSIS
    • 11.9     MEDTRONIC PLC
      • 11.9.1     OVERVIEW
      • 11.9.2     FINANCIALS
      • 11.9.3     PRODUCT PORTFOLIO
      • 11.9.4     KEY DEVELOPMENTS
      • 11.9.5     BUSINESS STRATEGY
      • 11.9.6     SWOT ANALYSIS
    • 11.10     NOVA BIOMEDICAL
      • 11.10.1     OVERVIEW
      • 11.10.2     FINANCIALS
      • 11.10.3     PRODUCT PORTFOLIO
      • 11.10.4     KEY DEVELOPMENTS
      • 11.10.5     BUSINESS STRATEGY
      • 11.10.6     SWOT ANALYSIS
    • 11.11     SIEMENS AG
      • 11.11.1     OVERVIEW
      • 11.11.2     FINANCIALS
      • 11.11.3     PRODUCT PORTFOLIO
      • 11.11.4     KEY DEVELOPMENTS
      • 11.11.5     BUSINESS STRATEGY
      • 11.11.6     SWOT ANALYSIS
    • 11.12     THERMOFISHER SCIENTIFIC INC.
      • 11.12.1     OVERVIEW
      • 11.12.2     FINANCIALS
      • 11.12.3     PRODUCT PORTFOLIO
      • 11.12.4     KEY DEVELOPMENTS
      • 11.12.5     BUSINESS STRATEGY
      • 11.12.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     POCD GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 2     POCD GLOBAL MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 3     POCD GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 4     POCD GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 5     POCD GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 6     SELF GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 7     CONTINUOUS GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 8     POCD INFECTIOUS DISEASE KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 9     POCD INFECTIOUS DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 10     HIV KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 11     HEPATITIS KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 12     TROPICAL DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 13     TUBERCULOSIS KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 14     HEALTHCARE-ASSOCIATED DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 15     RESPIRATORY DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 16     OTHER INFECTIOUS DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 17     POCD COAGULATION KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 18     POCD COAGULATION KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 19     PROTHROMBIN TIME(PT/INR) TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 20     ACTIVATED CLOTTING TIME(ACT/APTT) TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 21     POCD HEMATOLOGY TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 22     POCD PREGNANCY AND FERTILITY KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 23     POCD PREGNANCY AND FERTILITY TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 24     PREGNANCY TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 25     FERTILITY TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 26     POCD CARDIOMETABOLIC KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 27     POCD CARDIOMETABOLIC KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 28     POCD CARDIAC MARKERS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 29     POCD BLOOD GAS/ELECTROLYTES TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 30     POCD HBA1C TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 31     POCD LIPID TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 32     POCD TUMOR/CANCER MARKERS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 33     POCD URINALYSIS TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 34     POCD CHOLESTEROL TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 35     POCD DRUGS-OF-ABUSE TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 36     POCD OTHER TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 37     POCD GLOBAL MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
      • TABLE 38     POCD BIOSENSOR TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 39     POCD IMMUNOCHROMATOGRAPHIC TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 40     POCD PCR TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 41     POCD LAB-ON-A-CHIP TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 42     POCD OTHER TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 43     POCD GLOBAL MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
      • TABLE 44     PRESCRIPTION BASED TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 45     OVER THE COUNTER TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 46     POCD GLOBAL MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
      • TABLE 47     POCD BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 48     POCD URINE SAMPLE GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 49     POCD SALIVA SAMPLE GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 50     POCD OTHER SAMPLES GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 51     POCD GLOBAL MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
      • TABLE 52     POCD CLINICS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 53     POCD HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 54     POCD HOME HEALTHCARE GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 55     POCD OTHER END-USERS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • TABLE 56     NORTH AMERICAN POCD MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 57     NORTH AMERICAN POCD GLUCOSE MONITORING KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 58     NORTH AMERICAN POCD INFECTIOUS DIASEASE KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 59     NORTH AMERICAN POCD COAGULATION KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 60     NORTH AMERICAN POCD PREGNANCY AND FERTILITY KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 61     NORTH AMERICAN POCD CARDIOMETABOLIC KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 62     NORTH AMERICAN POCD MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
      • TABLE 63     NORTH AMERICAN POCD MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
      • TABLE 64     NORTH AMERICAN POCD MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
      • TABLE 65     NORTH AMERICAN POCD MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
      • TABLE 66     NORTH AMERICAN POCD MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • TABLE 67     EUROPEAN POCD MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 68     EUROPEAN POCD GLUCOSE MONITORING KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 69     EUROPEAN POCD INFECTIOUS DIASEASE KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 70     EUROPEAN POCD COAGULATION KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 71     EUROPEAN POCD PREGNANCY AND FERTILITY KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 72     EUROPEAN POCD CARDIOMETABOLIC KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 73     EUROPEAN POCD MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
      • TABLE 74     EUROPEAN POCD MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
      • TABLE 75     EUROPEAN POCD MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
      • TABLE 76     EUROPEAN POCD MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
      • TABLE 77     EUROPEAN POCD MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • TABLE 78     APAC POCD MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 79     APAC POCD GLUCOSE MONITORING KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 80     APAC POCD INFECTIOUS DIASEASE KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 81     APAC POCD COAGULATION KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 82     APAC POCD PREGNANCY AND FERTILITY KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 83     APAC POCD CARDIOMETABOLIC KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 84     APAC POCD MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
      • TABLE 85     APAC POCD MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
      • TABLE 86     APAC POCD MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
      • TABLE 87     APAC POCD MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
      • TABLE 88     APAC POCD MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • TABLE 89     ROW POCD MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
      • TABLE 90     ROW POCD GLUCOSE MONITORING KITS MARKET REVENUE BY TYPE (2015-2023) ($MN)
      • TABLE 91     ROW POCD INFECTIOUS DIASEASE KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 92     ROW POCD COAGULATION KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 93     ROW POCD PREGNANCY AND FERTILITY KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 94     ROW POCD CARDIOMETABOLIC KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
      • TABLE 95     ROW POCD MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
      • TABLE 96     ROW POCD MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
      • TABLE 97     ROW POCD MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
      • TABLE 98     ROW POCD MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
      • TABLE 99     ROW POCD MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
      • TABLE 100     APPROVALS (2015-2017)
      • TABLE 101     AGREEMENTS, PARTNERSHIPS & COLLABORATIONS (2015-2017)
      • TABLE 102     NEW PRODUCT LAUNCH(2015-2017)
      • TABLE 103     ACQUISITIONS (2015-2017)
      • TABLE 104     OTHER DEVELOPMENTS (2015-2017)
      • TABLE 105     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 106     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 107     ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 108     BECTON DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 109     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 110     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY LIFE SCIENCE SEGMENTS, (2014-2016) ($MN)
      • TABLE 111     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 112     BIOMEREIUX: TOTAL REVENUE AND R&D EXPENSES, (2014-2016*) ($MN)
      • TABLE 113     BIOMERIEUX: TOTAL REVENUE,BY SEGMENTS, (2014-2016*) ($MN)
      • TABLE 114     BIOMEREIUX: TOTAL REVENUE, BY CLINICAL SEGMENTS, (2014-2016*) ($MN)
      • TABLE 115     BIOMEREIUX: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016*) ($MN)
      • TABLE 116     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 117     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 118     DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016*) ($MN)
      • TABLE 119     DEXCOM INC: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 120     DEXCOM INC: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 121     ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 122     ROCHE HOLDINGS AG: TOTAL REVENUE BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 123     ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES, (2014-2016) ($MN)
      • TABLE 124     ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 125     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 126     JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 127     JOHNSON & JOHNSON: TOTAL REVENUE, BY MEDICAL DEVICE SEGMENTS, (2014-2016) ($MN)
      • TABLE 128     JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 129     MEDTRONIC PLC: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
      • TABLE 130     MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 131     MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
      • TABLE 132     SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
      • TABLE 133     SIEMENS AG: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
      • TABLE 134     SIEMENS AG : TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
      • TABLE 135     THERMOFISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 136     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
      • TABLE 137     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)

      LIST OF FIGURES

      • FIGURE 1     POCD GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: POINT OF CARE DIAGNOSTICS GLOBAL MARKET
      • FIGURE 3     POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     POINT OF CARE DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     POINT OF CARE DIAGNOSTICS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     POINT OF CARE DIAGNOSTICS MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     POINT OF CARE DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     POINT OF CARE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016
      • FIGURE 10     GLUCOSE MONITORING KITS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016 (%)
      • FIGURE 11     CONTINUOUS GLUCOSE MONITORING KITS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016 (%)
      • FIGURE 12     COAGULATION TESTING KITS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016 (%)
      • FIGURE 13     CARDIAC MARKERS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016 (%)
      • FIGURE 14     POINT OF CARE DIAGNOSTICS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 15     POCD GLOBAL MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 16     POCD GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY TYPE (2016 V/S 2023) ($MN)
      • FIGURE 17     POCD INFECTIOUS DISEASE KITS GLOBAL MARKET REVENUE, BY TYPE (2016 V/S 2023) ($MN)
      • FIGURE 18     POCD COAGULATION MONITORING KITS GLOBAL MARKET REVENUE, BY TYPE (2015 V/S 2023) ($MN)
      • FIGURE 19     POCD GLOBAL MARKET REVENUE, BY REGION (2015 V/S 2023) ($MN)
      • FIGURE 20     POCD CARDIOMETABOLIC KITS GLOBAL MARKET REVENUE, BY TYPE (2016 V/S 2023) ($MN)
      • FIGURE 21     POCD GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2016 V/S 2023) ($MN)
      • FIGURE 22     POCD GLOBAL MARKET REVENUE, BY PRESCRIPTION MODE, (2016 V/S 2023) ($MN)
      • FIGURE 23     POCD GLOBAL MARKET REVENUE, BY SAMPLE (2016 V/S 2023) ($MN)
      • FIGURE 24     POCD GLOBAL MARKET REVENUE, BY END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 25     POCD GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
      • FIGURE 26     NORTH AMERICAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 27     NORTH AMERICAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 28     U.S. POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 29     U.S. POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 30     OTHERS NORTH AMERICAN POCD MARKET SHARE, BY PRODUCTS, (2016 V/S 2023) ($MN)
      • FIGURE 31     OTHERS NORTH AMERICAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 32     EUROPEAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 33     EUROPEAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 34     GERMANY POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 35     GERMANY POCD MARKET SHARE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 36     ITALY POCD MARKET REVENUE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 37     ITALY POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 38     FRANCE POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 39     FRANCE POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 40     OTHERS EUROPEAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 41     OTHERS EUROPEAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 42     APAC POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 43     APAC POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 44     JAPAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 45     JAPAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 46     CHINA POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 47     CHINA POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 48     INDIAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 49     INDIAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 50     OTHERS APAC POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 51     OTHERS APAC POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 52     ROW POCD MARKET SHARE, BY PRODUCTS, (2016 V/S 2023) (%)
      • FIGURE 53     ROW POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 54     BRAZIL POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 55     BRAZIL POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 56     REST OF LATIN AMERICAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 57     REST OF LATIN AMERICAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 58     MIDDLE EAST & OTHERS POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
      • FIGURE 59     MIDDLE EAST & OTHERS POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
      • FIGURE 60     KEY GROWTH STRATEGIES, (2015-2017)
      • FIGURE 61     SWOT: ABBOTT LABORATORIES, INC
      • FIGURE 62     SWOT: ASCENSIA DIABETES CARE
      • FIGURE 63     SWOT: BECTON DICKINSON AND COMPANY
      • FIGURE 64     SWOT: BIOMEREIUX
      • FIGURE 65     SWOT: DANAHER CORPORATION
      • FIGURE 66     SWOT: DEXCOM INC.
      • FIGURE 67     SWOT: F.HOFFMANN-LA ROCHE HOLDINGS
      • FIGURE 68     SWOT: JOHNSON & JOHNSON
      • FIGURE 69     SWOT: MEDTRONIC PLC
      • FIGURE 70     SWOT: NOVA BIOMEDICAL
      • FIGURE 71     SWOT: SIEMENS AG
      • FIGURE 72     SWOT: THERMOFISHER SCIENTIFIC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ASCENSIA DIABETES CARE HOLDINGS AG
      • 2     A. MENARINI DIAGNOSTICS S.R.L
      • 3     ABAXIS, INC.,
      • 4     ABBOTT LABORATORIES, INC.
      • 5     ACCRIVA DIAGNOSTICS
      • 6     ACCUREX BIOMEDICAL
      • 7     ACCUTECH INC
      • 8     ACON LABORATORIES, INC
      • 9     ADALTIS
      • 10     ALFA SCIENTIFIC DESIGNS
      • 11     ANI BIOTECH OY,
      • 12     AQUILA DIAGNOSTICS INC.
      • 13     ARBORVITA
      • 14     ARKRAY, INC
      • 15     ATLAS GENETICS
      • 16     ATOMO DIAGNOSTICS
      • 17     BEACON BIOMEDICAL
      • 18     BECTON DICKINSON AND COMPANY
      • 19     BIO-AMD
      • 20     BIOLIGHT LIFE SCIENCES
      • 21     BIOLYTICAL LABORATORIES INC.
      • 22     BIOMEDICA
      • 23     BIOMERIEUX
      • 24     BTNX INC
      • 25     CARDINAL HEALTH
      • 26     CHEMBIO DIAGNOSTIC SYSTEMS, INC.
      • 27     CHURCH & DWIGHT CO., INC.,
      • 28     COELIAC AUSTRALIA
      • 29     CURIOSITY DIAGNOSTICS
      • 30     DAKTARI DIAGNOSTICS
      • 31     DANAHER CORPORATION
      • 32     DCC PLC., 
      • 33     DEXCOM INC.
      • 34     DIABETOMICS
      • 35     DIASYS DIAGONSTICS SYSTEMS, GmbH
      • 36     EKF DIAGNOSTICS
      • 37     ELITECHGROUP MOLECULAR DIAGNOSTICS
      • 38     ENIGMA DIAGNOSTICS
      • 39     ENTERIX, INC
      • 40     EPITOPE DIAGNOSTICS INC,
      • 41     ERBA DIAGNOSTICS MANNHEIM GMBH
      • 42     EUROMEDIX POC NV/SA
      • 43     EXOSOMES DIAGNOSTICS
      • 44     F. HOFFMANN-LA ROCHE AG
      • 45     FANNIN
      • 46     FIRST DIAGNOSTICS CORPORATION
      • 47     GLYSENS, INC.
      • 48     GLYSURE
      • 49     HELENA LABORATORIES
      • 50     HEMOSURE INC.,
      • 51     HORIBA
      • 52     HUMOR DIAGNOSTICA
      • 53     INBIOS
      • 54     INSILIXA, INC
      • 55     INSTRUMENTATION LABORATORIES
      • 56     INTERNATIONAL BIOMEDICAL
      • 57     INTERNATIONAL TECHNIDYNE CORPORATION(ITC)
      • 58     IONICONANALYTIK GMBH
      • 59     JOHNSON & JOHNSON (J&J)
      • 60     KAMINENI LIFESCIENCE
      • 61     KMC SYSTEMS
      • 62     KOROGLU MEDICAL DEVICES LTD
      • 63     LABSYSTEMS DIAGNOSTICS OY
      • 64     LABTICIAN OPHTHALMICS, INC
      • 65     LIFESCAN
      • 66     LIPID PLUS
      • 67     MBIO DIAGNOSTICS, INC
      • 68     MEDICA CORPORATION
      • 69     MEDMIRA INC.
      • 70     MEDTRONIC PLC
      • 71     MERIDIAN BIOSCIENCE, INC,
      • 72     MINDRAY
      • 73     NANOENTEK
      • 74     NANOREPRO
      • 75     NANOSPEED DIAGNOSTICS
      • 76     NEMAURA MEDICAL
      • 77     NGAIO DIAGNOSTICS
      • 78     NIPRO DIAGNOSTICS
      • 79     NOVA BIOMEDICAL
      • 80     NOVAMAX
      • 81     NOWDIAGNOSTICS
      • 82     OASIS DIAGNOSTICS
      • 83     OMEGA DIAGNOSTICS
      • 84     OMNICA CORPORATION
      • 85     ONCOGENESIS
      • 86     OPERON BIOTECH & HEALTHCARE
      • 87     OPKO DIAGNOSTICS
      • 88     OPHTHALMIC INSTRUMENT COMPANY
      • 89     OPTISCAN
      • 90     ORASURE TECHNOLOGIES, INC.
      • 91     PERKIN ELMER
      • 92     PHOENIX MEDCARE
      • 93     POC MEDICAL SYSTEMS, INC.,
      • 94     POLYMER TECHNOLOGY SYSTEMS, INC
      • 95     PREMIER MEDICAL CORPORATION LTD.
      • 96     PRESTIGE BRANDS HOLDINGS, INC.,
      • 97     PROBE SCIENTIFIC
      • 98     PRODIGY
      • 99     PTS DIAGNOSTICS
      • 100     QUIDEL CORPORATION
      • 101     RESPONSE BIOMEDICAL
      • 102     RPS DIAGNOSTICS
      • 103     SENSEONICS
      • 104     SIEMENS AG
      • 105     SIMPLE DIAGNOSTICS
      • 106     SKANNEX AS
      • 107     SORRENTO THERAPEUTICS
      • 108     SUGENTECH INC. 
      • 109     SWISS PRECISION DIAGNOSTICS GMBH
      • 110     SYSMEX CORPORATION
      • 111     TB BIOSCIENCES, INC
      • 112     TEL-ARRAY
      • 113     TERUMO CORPORATION
      • 114     THERMOFISHER SCIENTIFIC, INC.
      • 115     TRANSASIA BIO-MEDICALS
      • 116     TRINITY BIOTECH
      • 117     TRIVITRON HEALTHCARE
      • 118     UNIVERSAL BIOSENSORS
      • 119     US DIAGNOSTICS
      • 120     ZBX CORPORATION